ACADIA Pharmaceuticals Inc. (ACAD)
NASDAQ: ACADHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 7, 4:00 PM ET · Delayed 15 min
ACAD stock chart
Technical analysisKey statistics
All statistics- Market cap
- $3.39B
- P/E (TTM)
- 8.85
- Forward P/E
- 22.12
- EPS (TTM)
- $2.22
- Dividend yield
- None
- 52-week range
- 19.46 – 30.96
- Day range
- 19.46 – 19.80
- Volume / Avg
- 1.78M / 1.84M
- Beta
- —
- Shares outstanding
- 172.31M
- Next earnings
- Nov 4, 2026
52-week range
ACAD stock today
ACADIA Pharmaceuticals (ACAD) closed at $19.65 on Oct 7, down 0.46% (-$0.09), versus the S&P 500's 0.22% decline. Shares are 36.5% below their 52-week high of $30.96, set on Aug 19, 2026 and 1.0% above the 52-week low of $19.46, near the bottom of the past year's range. ACAD is down 26.4% year to date, underperforming the S&P 500 (+14.0%). Over the past 12 months, the stock has lost 8.8%.
ACADIA Pharmaceuticals trades at 8.9x its trailing twelve-month earnings per share of $2.22. Its forward P/E of 22.1x is higher than the trailing multiple, which means analysts expect earnings to decline over the next year. ACADIA Pharmaceuticals's next earnings report is expected on Nov 4, 2026.
Summary generated from market data by MetaCap's automated system. Methodology
About ACADIA Pharmaceuticals
Company profileACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for neurological and rare disease in North America. The company offers NUPLAZID (pimavanserin), a selective serotonin inverse agonist/antagonist for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 to treat the symptoms of Rett syndrome by reducing neuroinflammation and supporting synaptic function. It also develops remlifanserin, which is in phase 2 clinical trial for the treatment of alzheimer's disease psychosis and lewy body dementia psychosis; ACP-211, which is in phase 2 clinical trial to treat major depressive disorder; ACP-711, which is in phase I clinical trial for the treatment of essential tremor; and ACP-271, a GPR88 agonist for the treatment of tardive dyskinesia and huntington's disease and is in phase I trial.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Ms. Catherine E. Owen Adams
- Headquarters
- San Diego, CA
- Employees
- 796
- IPO year
- 1985
- Website
- acadia.com
Analyst forecast
ForecastConsensus (20 analysts)
buy
Avg. price target
$32.16+63.66%
- Strong buy 4
- Buy 11
- Hold 4
- Sell 1
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Next report
- Nov 4, 2026
- EPS estimate
- $0.21
ACADIA Pharmaceuticals peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| AMLXAmylyx Pharmaceuticals Inc. | 27.43 | -2.18% | $3.44B | vs ACAD |
| IDYAIDEAYA Biosciences Inc. | 36.26 | -1.01% | $3.50B | vs ACAD |
| XENEXenon Pharmaceuticals Inc. | 36.41 | -0.44% | $3.53B | vs ACAD |
| PBLSParabilis Medicines Inc. | 28.82 | -0.14% | $3.56B | vs ACAD |
| VKTXViking Therapeutics Inc. | 28.54 | +0.56% | $3.63B | vs ACAD |
| LEGNLegend Biotech Corporation ADR | 19.12 | +2.14% | $3.72B | vs ACAD |
| RCUSArcus Biosciences Inc. | 24.52 | +0.99% | $3.08B | vs ACAD |
| ARQTArcutis Biotherapeutics Inc. | 24.17 | +1.05% | $3.04B | vs ACAD |
Indexes, lists and sector
ACADIA Pharmaceuticals stock FAQ
What is ACADIA Pharmaceuticals's stock price today?
ACAD last traded at $19.65 as of Oct 7, 4:00 PM EDT, down 0.46% on the day. Prices are delayed at least 15 minutes.
When is ACADIA Pharmaceuticals's next earnings date?
ACADIA Pharmaceuticals is expected to report earnings on Wednesday, November 4, 2026. Analysts expect EPS of $0.21.
What is ACAD's P/E ratio?
ACAD trades at a trailing P/E ratio of 8.85 and a forward P/E of 22.12.
Who is ACADIA Pharmaceuticals's CEO?
Ms. Catherine E. Owen Adams is the chief executive officer of ACADIA Pharmaceuticals Inc., which has about 796 employees.
What is the ACAD 52-week high?
The 52-week high for ACAD is $30.96 and the 52-week low is $19.46. The stock is currently 36.5% below its high.